• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case

Let's look at the charts and indicators to round out the picture.
By BRUCE KAMICH
Feb 19, 2019 | 10:19 AM EST
Stocks quotes in this article: JNJ, AAPL

For his "Executive Decision" segment of Mad Money Friday night, Jim Cramer sat down with Alex Gorsky, chairman and CEO of Johnson & Johnson (JNJ) . Gorsky said that JNJ just completed another solid quarter and they remain very excited about the outlook for 2019.

The Food and Drug Administration just approved Esketamine, the first new treatment for severe depression in the past 30 years. He said nearly five million patients suffer from depression in the U.S.

Gorsky was also upbeat about J&J's recent partnership with Apple (AAPL) to help bring new apps and functionality to the Apple iWatch. He said the combination of technology and healthcare can be very powerful and help save lives and money for our healthcare system. The Apple iWatch can already detect conditions like Afib, he said, but that's only just the beginning.

Robotics is another area Gorsky was excited about. He said only 5% of surgeries today are performed digitally or with robotics and that leaves a huge area to improve patient outcomes.

Sounds like an upbeat fundamental story but let's look at the charts and indicators to round out the picture.

In this daily bar chart of JNJ, below, we can see that prices have recovered about half of its December slide. JNJ made a low in late December along with the broad market and it has since recovered.

Prices are above the slightly rising 200-day moving average line and above the still declining 50-day line. Because moving averages lag the market the 50-day line is now crossing below the 200-day line for a belated and potentially bearish death cross of these tow indicators. The trading volume has not really increased from the late December low and thus not really confirming the price rise.

The daily On-Balance-Volume (OBV) line is a simpler way to look at volume and it was flat from December to late January, and did not signal more aggressive buying until recently.

The trend-following Moving Average Convergence Divergence (MACD) oscillator crossed above the zero line last week to generate an outright go long signal.

In this weekly bar chart of JNJ, below, the price decline of December does not look so bearish. If you look at the decline in January 2018 you have a point to compare. Prices held support in the $120 area earlier in 2018 and stopped short of that area in late December. JNJ is above the slightly rising 40-week moving average line. 

The weekly OBV line shows a little improvement from its December low but is well below its best level of 2018.

The weekly MACD oscillator is close to crossing to the upside from below the zero line for a cover shorts buy signal. An outright buy signal may not be that far off either.

In this Point and Figure chart of JNJ, below, we can see that prices are in an up column of X's. A possible upside price target of $153.74 is being projected. This would be a new high for the move up but not that bullish of a target if it was reached.

Bottom line strategy: JNJ is a brand name that everyone seems to know but that does not mean that everything on the price chart is in agreement and bullish. JNJ could work higher and we have a $153 price target from our Point and Figure chart, however, chart resistance in the $140-$149 area from November and December could stall or even reverse further strength. JNJ will have to show me more from a technical perspective to make me feel comfortable with recommending the long side.

(Johnson & Johnson and Apple are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ or AAPL? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals

More from Investing

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login